Diethylstilbestrol (DES) Pancreatic Cancer Lawsuits: Seeking Justice for DES Daughters
Have You Been Diagnosed with Pancreatic Cancer After Prenatal DES Exposure?
If you were prenatally exposed to Diethylstilbestrol (DES) and have been diagnosed with pancreatic cancer, you may have legal options to pursue justice. Emerging research has identified a significant link between prenatal DES exposure and an increased risk of pancreatic cancer, and law firms like ours are pioneering this groundbreaking litigation.
What is DES?
Diethylstilbestrol (DES) is a synthetic estrogen that was widely prescribed to pregnant women from the 1940s to the 1970s to prevent miscarriages and pregnancy complications. Unfortunately, this drug was later linked to serious health risks in the offspring of those who took it, now known as DES Daughters and DES Sons.
Most lawsuits involving DES have focused on clear-cell adenocarcinoma, breast cancer, and reproductive disorders. However, new epidemiological studies suggest that DES-exposed women may also have an elevated risk of pancreatic cancer—a life-threatening disease with limited treatment options and high mortality rates.
New Scientific Evidence Linking DES to Pancreatic Cancer
Two major studies conducted by the National Cancer Institute (NCI) DES Combined Cohort Study have analyzed the long-term cancer risks associated with prenatal DES exposure:
2019 Study (Troisi et al.) – Found that DES-exposed women had a 2.43 times higher risk (SIR = 2.43, 95% CI: 1.21–4.34) of pancreatic cancer compared to the general population. This represents a 143% increased relative risk.
2020 Study (Troisi et al.) – With extended follow-up data, researchers found that DES-exposed women had a 4.1-fold increased risk (HR = 4.1, 95% CI: 0.84–20) compared to unexposed women in the study cohort. The SIR dropped slightly to 1.9 (95% CI: 1.0–3.2), indicating a 90% increased risk compared to the general population. The HR suggests a 310% increased relative risk compared to unexposed women in the study.
These studies support that DES-exposed women face a significantly increased risk of developing pancreatic cancer, warranting further legal action.
Recent studies have established a significant association between chronic pancreatitis and an increased risk of pancreatic cancer. A multicenter cohort study published in the New England Journal of Medicine reported that individuals with chronic pancreatitis had a standardized incidence ratio (SIR) of 26.3 for developing pancreatic cancer, indicating a markedly higher risk compared to the general population.
Similarly, the American Cancer Society recognizes chronic pancreatitis as a notable risk factor for pancreatic cancer.
These findings underscore the importance of monitoring and managing pancreatic health, especially for those with a history of pancreatitis. While pancreatic cancer remains a relatively rare disease, the fact that DES exposure significantly increases the risk is critical evidence in litigation.
Why This Matters in a Lawsuit
The pharmaceutical industry failed to test DES and warn pregnant women and the public about the long-term risks of DES.
New scientific data provides strong evidence that DES exposure is linked to pancreatic cancer.
If you qualify, you may be eligible for compensation for medical expenses, pain and suffering, and wrongful death claims.
A Proven Leader in DES Litigation
Attorney Julie Oliver-Zhang is a nationally-recognized leader in DES litigation, bringing years of experience advocating for DES-exposed individuals harmed by pharmaceutical negligence. As a key attorney in the groundbreaking DES breast cancer lawsuit, Ms. Oliver-Zhang played a pivotal role in challenging major drug manufacturers on behalf of women who developed breast cancer following prenatal DES exposure.
Her work led to critical legal precedents, reinforcing the right of DES Daughters to seek justice. With deep knowledge of DES-related science and litigation strategy, she is now at the forefront of new DES pancreatic cancer cases, helping victims hold corporations accountable for the long-term, undisclosed risks of DES exposure.
If you or a loved one has been affected by DES exposure, contact us today for a free case evaluation.
Who Qualifies for a DES Pancreatic Cancer Lawsuit?
To qualify for a DES daughter pancreatic cancer lawsuit, you must meet the following criteria:
✔ You were prenatally exposed to DES. This means your mother took DES during pregnancy, typically between the 1940s and 1970s.
✔ You have been diagnosed with pancreatic cancer. This includes any subtype of pancreatic malignancy.
✔ You were born between 1953 and 1971. This is the primary timeframe when DES was prescribed to pregnant women.
✔ You have medical records or other documentation linking your pancreatic cancer diagnosis to your medical history.
✔ Your claim is still within the statute of limitations. Many states allow exceptions for latent diseases like cancer, but time may be limited.
If you are unsure whether you qualify, contact us for a free case evaluation.
How Our Law Firm Can Help
Our legal team is leading the fight for DES Daughters who are suffering from pancreatic cancer and seeking justice against the pharmaceutical companies responsible. We provide:
- Comprehensive case reviews to determine eligibility.
- Collaboration with leading medical experts to strengthen your case.
- Aggressive litigation strategies based on the latest scientific findings.
- No upfront legal fees – We only get paid if you win.
Act Now: Time May Be Running Out
If you or a loved one has been diagnosed with pancreatic cancer, or has unfortunately passed away due to pancreatic cancer and believe DES exposure is to blame, you may be entitled to compensation. However, statutes of limitations vary by state, so do not wait to take action.
Call Oliver-Zhang Law Today for a Free Consultation at 202-643-1110 or email at [email protected]
🌐 www.oliverzhanglaw.com
We are ready to fight for you. Don’t let pharmaceutical companies escape accountability. Contact us now to start your DES pancreatic cancer lawsuit.
